Offerings / Regulation CF / KAHF Biotech, Inc.

KAHF Biotech, Inc.

Regulation Crowdfunding offering on Wefunder · Form C filed February 24, 2026 · Rochester, New York

SAFEPre-revenueCorporation, DelawareHealthcareBiotechnology: preclinical cancer therapeutics

KAHF Biotech, Inc., a Delaware corporation organized April 29, 2025 with offices in Rochester, New York, is developing antibody-based cancer therapeutics that target the KAHF receptor, with pancreatic ductal adenocarcinoma as its lead indication. The company is pre-revenue and preclinical, reports $0 in assets and revenue, and is offering SAFEs with a $50,000 target and a $124,000 maximum through Wefunder Portal LLC.

Registry notesThe MD&A says no capital contributions have been received from founders or investors but also cites founder cash contributions under $10,000, and it reports $100 in cash as of January 2026 and about $300,000 in expected monthly expenses against a stated $0 burn rate. The founder is the sole director, officer and 100% holder, is described as a part-time officer, and the filing estimates $50 million of additional capital is needed to reach revenue.

Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.

Offering terms

Security: Simple Agreement for Future Equity (SAFE)
Maximum: $124,000.00
Price: $1.00 per unit
Pricing method: Pro-rated portion of the total principal value of $50,000; interests will be sold in increments of $1; each investment is convertible to one share of stock as described under Item 13.
Deadline: July 29, 2026
Oversubscriptions: Accepted
Intermediary: Wefunder Portal LLC
Funding portal, SEC file 007-00033
Intermediary fee: 7.9% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
Intermediary equity: No
Co-issuer: KAHF Biotech I, a series of Wefunder SPV, LLC

Financials as filed

Item	Most recent FY	Prior FY
Revenue	$0	$0
Cost of goods sold	$0	$0
Net income (loss)	$0	$0
Total assets	$0	$0
Cash and equivalents	$0	$0
Accounts receivable	$0	$0
Short-term debt	$0	$0
Long-term debt	$0	$0
Taxes paid	$0	$0

Two fiscal years as reported on the Form C cover sheet. 1 employees. Offered in 56 states.

Use of proceeds

At the $50,000 target: 70% for therapeutic monoclonal antibody development and in vitro data development, 16.1% for legal, 7.9% Wefunder fee, and 6% for lab space and company trademark and tax. At the $124,000 maximum: the same percentages apply, with the minimum raise funding antibody development and provisional patent filings and the maximum raise funding preliminary in vitro and in vivo experiments.

Valuation

SAFE with a post-money valuation cap of $10,000,000 and an 80% discount rate (20% discount). Price per interest is $1.00, based on pro-rated portion of the $50,000 target. The offering price was set arbitrarily by the company without an independent appraisal or investment bank input.

Prior raises

Not stated

Financial statements

Financial statements for inception (April 29, 2025) to December 10, 2025 are labeled unaudited; the CEO certifies they are true and complete in all material respects. No independent CPA review or audit is stated.